Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734665 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL2733252 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL23674957 | 1.00 | ALDH1A1 (0.71) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL2734649 | 0.98 | ALDH1A1 (0.74) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL6331035 | 0.92 | ALDH1A1 (0.77) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL8970703 | 0.90 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL4001371 | 0.90 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL8971703 | 0.90 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL8971186 | 0.90 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 | |
| SCHEMBL8971393 | 0.90 | ALDH1A1 (0.87) | ALDH1A1CYP2C19CYP3A4CYP2C9MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106337187-B | Double stimuli responsive type nano containers of a kind of acid/base and preparation method thereof | 南京理工大学 | 2018-10-12 | — | — | CN | claimed |
| CN-106337187-A | Acid/base double stimulation responsive nanometer container and preparation method thereof | 南京理工大学 | 2017-01-18 | — | — | CN | claimed |
| CN-106337187-B | Double stimuli responsive type nano containers of a kind of acid/base and preparation method thereof | 南京理工大学 | 2018-10-12 | — | — | CN | disclosed |
| CN-106337187-A | Acid/base double stimulation responsive nanometer container and preparation method thereof | 南京理工大学 | 2017-01-18 | — | — | CN | disclosed |
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | WISCONSIN MED COLLEGE INC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8466130-B2 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | COLBY PHARMACEUTICAL COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2139522-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | Colby Pharmaceutical Company (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008109740-A2 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338110-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | ALDH1A1 1738/4885CYP2C19 1985/4885CYP3A4 3215/4885 |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | ALDH1A1 1738/4885CYP2C19 1985/4885CYP3A4 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.